Global tumor protein p53/p63 interactome: Making a case for cisplatin chemoresistance

Cell Cycle

Volumn 11, Issue 12, 2012, Pages 2367-2379

  Huang, Yiping ^a   Jeong, Jun Seop ^a   Okamura, Jun ^a   Sook Kim, Myoung ^a   Zhu, Heng ^a   Guerrero Preston, Rafael ^a   Ratovitski, Edward A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cisplatin; P53; P63; Protein interactions; Squamous cell carcinomas

Indexed keywords

ACIN1 PROTEIN; CARRIER PROTEIN; CISPLATIN; GLYCINE; MESSENGER RNA; POLYHISTIDINE TAG; PROTEIN P53; PROTEIN P63; SERINE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NP63 ALPHA; UNCLASSIFIED DRUG;

AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL DEATH; CELL VIABILITY; CHEMOSENSITIVITY; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EXPOSURE; GENE REPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY; MASS SPECTROMETRY; MEDIATOR; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEOMICS; RNA SPLICING; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TANDEM MASS SPECTROMETRY; TUMOR CELL;

EID: 84862845005     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.20863     Document Type: Article

References (73)

1. Helmbach H, Kern MA, Rossmann E, Renz K, Kissel C, Gschwendt B, et al. Drug resistance towards etoposide and cisplatin in human melanoma cells is associated with drug-dependent apoptosis deficiency. J Invest Dermatol 2002; 118:923-32; PMID:12060385; http://dx.doi.org/10.1046/j.1523-747.2002.01786.x.
2. Zangen R, Ratovitski EA, Sidransky D. DeltaNp63αlevels correlate with clinical tumor response to cisplatin. Cell Cycle 2005; 4:1313-5; PMID:16123597; http://dx.doi.org/10.4161/cc.4.10.2066.
3. Kelland L. The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 2007; 7:573-84; PMID:17625587; http://dx.doi.org/10.1038/nrc2167.
4. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, et al. P63 and p73 are required for TP53- dependent apoptosis in response to DNA damage. Nature 2002; 416:560-4; PMID:11932750; http://dx.doi.org/10.1038/416560a.
5. Rocco JW, Leong CO, Kuperwasser N, DeYoung MP, Ellisen LW. p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006; 9:45-56; PMID:16413471; http://dx.doi.org/10.1016/j.ccr.2005. 12.013.
6. Huang Y, Sen T, Nagpal J, Upadhyay S, Trink B, Ratovitski E, et al. ATM kinase is a master switch for the ΔNp63α phosphorylation/degradation in human head and neck squamous cell carcinoma cells upon DNA damage. Cell Cycle 2008; 7:2846- 55; PMID:18769144; http://dx.doi.org/10.4161/cc.7.18.6627.
7. Huang Y, Chuang AY, Romano RA, Liegeois NJ, Sinha S, Trink B, et al. Phospho-ΔNp63α/NF-Y protein complex transcriptionally regulates DDIT3 expression in squamous cell carcinoma cells upon cisplatin exposure. Cell Cycle 2010; 9:332-42; http://dx.doi.org/10.4161/cc.9.2.10432.
8. Collavin L, Lunardi A, Del Sal G. p53-family proteins and their regulators: hubs and spokes in tumor suppression. Cell Death Differ 2010; 17:901- 11; PMID:20379196; http://dx.doi.org/10.1038/cdd.2010.35.
9. Tozluoǧlu M, Karaca E, Haliloglu T, Nussinov R. Cataloging and organizing p73 interactions in cell cycle arrest and apoptosis. Nucleic Acids Res 2008; 36:5033- 49; PMID:18660513; http://dx.doi.org/10.1093/nar/gkn481.
10. Ratovitski EA, Patturajan M, Hibi K, Trink B, Yamaguchi K, Sidransky D. p53 associates with and targets Δ Np63 into a protein degradation pathway. Proc Natl Acad Sci USA 2001; 98:1817-22; PMID:11172034; http://dx.doi.org/10. 1073/pnas.98.4.1817.
11. Zeng SX, Dai MS, Keller DM, Lu H. SSRP1 functions as a co-activator of the transcriptional activator p63. EMBO J 2002; 21:5487-97; PMID:12374749; http://dx.doi.org/10.1093/emboj/cdf540.
12. Patturajan M, Nomoto S, Sommer M, Fomenkov A, Hibi K, Zangen R, et al. DeltaNp63 induces β-catenin nuclear accumulation and signaling. Cancer Cell 2002; 1:369-79; PMID:12086851; http://dx.doi.org/10.1016/S1535-6108(02)00057-0.
13. Fomenkov A, Huang YP, Topaloglu O, Brechman A, Osada M, Fomenkova T, et al. P63α mutations lead to aberrant splicing of keratinocyte growth factor receptor in the Hay-Wells syndrome. J Biol Chem 2003; 278:23906-14; PMID:12692135; http://dx.doi.org/10.1074/jbc.M300746200.
14. Huang YP, Wu G, Guo Z, Osada M, Fomenkov T, Park HL, et al. Altered sumoylation of p63α contributes to the split-hand/foot malformation phenotype. Cell Cycle 2004; 3:1587-96; PMID:15539951; http://dx.doi.org/10.4161/ cc.3.12.1290.
15. MacPartlin M, Zeng S, Lee H, Stauffer D, Jin Y, Thayer M, et al. p300 regulates p63 transcriptional activity. J Biol Chem 2005; 280:30604-10; PMID:15965232;http://dx.doi.org/10.1074/jbc.M503352200.
16. Rossi M, Aqeilan RI, Neale M, Candi E, Salomoni P, Knight RA, et al. The E3 ubiquitin ligase Itch controls the protein stability of p63. Proc Natl Acad Sci USA 2006; 103:12753-8; PMID:16908849; http://dx.doi.org/10.1073/pnas. 0603449103.
17. Wang N, Guo L, Rueda BR, Tilly JL. Cables1 protects p63 from proteasomal degradation to ensure deletion of cells after genotoxic stress. EMBO Rep 2010; 11:633-9; PMID:20559324; http://dx.doi.org/10.1038/embor.2010.82.
18. Chatterjee A, Chang X, Sen T, Ravi R, Bedi A, Sidransky D. Regulation of p53 family member isoform DeltaNp63alpha by the nuclear factorkappaB targeting kinase IkappaB kinase beta. Cancer Res 2010; 70:1419-29; PMID:20145131; http://dx.doi.org/10.1158/0008-5472.CAN-09-2613.
19. Amoresano A, Di Costanzo A, Leo G, Di Cunto F, La Mantia G, Guerrini L, et al. Identification of DeltaNp63α protein interactions by mass spectrometry. J Proteome Res 2010; 9:2042-8; PMID:20085233;http://dx.doi.org/10. 1021/pr9011156.
20. Zhu H, Bilgin M, Bangham R, Hall D, Casamayor A, Bertone P, et al. Global analysis of protein activities using proteome chips. Science 2001; 293:2101- 5; PMID:11474067; http://dx.doi.org/10.1126/science.1062191.
21. Bai Y, Markham K, Chen F, Weerasekera R, Watts J, Horne P, et al. The in vivo brain interactome of the amyloid precursor protein. Mol Cell Proteomics 2008; 7:15-34; PMID:17934213; http://dx.doi.org/10.1074/mcp.M700077-MCP200.
22. Schweitzer B, Predki P, Snyder M. Microarrays to characterize protein interactions on a whole-proteome scale. Proteomics 2003; 3:2190-9; PMID:14595818; http://dx.doi.org/10.1002/pmic.200300610.
23. Schnack C, Hengerer B, Gillardon F. Identification of novel substrates for Cdk5 and new targets for Cdk5 inhibitors using high-density protein microarrays. Proteomics 2008; 8:1980-6; PMID:18491313; http://dx.doi.org/10. 1002/pmic.200701063.
24. O'Connell DJ, Bauer MC, O'Brien J, Johnson WM, Divizio CA, O'Kane SL, et al. Integrated protein array screening and high throughput validation of 70 novel neural calmodulin-binding proteins. Mol Cell Proteomics 2010; 9:1118-32; PMID:20068228; http://dx.doi.org/10.1074/mcp.M900324-MCP200.
25. McFarland MA, Ellis CE, Markey SP, Nussbaum RL. Proteomics analysis identifies phosphorylation-dependent α-synuclein protein interactions. Mol Cell Proteomics 2008; 7:2123-37; PMID:18614564; http://dx.doi.org/10.1074/mcp. M800116-MCP200.
26. Pflieger D, Jünger MA, Müller M, Rinner O, Lee H, Gehrig PM, et al. Quantitative proteomic analysis of protein complexes: concurrent identification of interactors and their state of phosphorylation. Mol Cell Proteomics 2008; 7:326-46; PMID:17956857; http://dx.doi.org/10.1074/mcp.M700282- MCP200.
27. Bousquet-Dubouch MP, Baudelet E, Guérin F, Matondo M, Uttenweiler-Joseph S, Burlet-Schiltz O, et al. Affinity purification strategy to capture human endogenous proteasome complexes diversity and to identify proteasome-interacting proteins. Mol Cell Proteomics 2009; 8:1150-64; PMID:19193609; http://dx.doi.org/10.1074/mcp.M800193-MCP200.
28. Chen LC, Chung IC, Hsueh C, Tsang NM, Chi LM, Liang Y, et al. The antiapoptotic protein, FLIP, is regulated by heterogeneous nuclear ribonucleoprotein K and correlates with poor overall survival of nasopharyngeal carcinoma patients. Cell Death Differ 2010; 17:1463-73; PMID:20224598; http://dx.doi.org/10.1038/cdd.2010.24.
29. Kaake RM, Wang X, Huang L. Profiling of protein interaction networks of protein complexes using affinity purification and quantitative mass spectrometry. Mol Cell Proteomics 2010; 9:1650-65; PMID:20445003; http://dx.doi.org/10.1074/mcp.R110.000265.
30. Moore MJ, Wang Q, Kennedy CJ, Silver PA. An alternative splicing network links cell cycle control to apoptosis. Cell 2010; 142:625-36; PMID:20705336; http://dx.doi.org/10.1016/j.cell.2010.07.019.
31. Jang SW, Yang SJ, Ehlén A, Dong S, Khoury H, Chen J, et al. Serine/arginine protein-specific kinase 2 promotes leukemia cell proliferation by phosphorylating acinus and regulating cyclin A1. Cancer Res 2008; 68:4559-70; PMID:18559500; http://dx.doi.org/10.1158/0008-5472.CAN-08-0021.
32. Zhong XY, Ding JH, Adams JA, Ghosh G, Fu XD. Regulation of SR protein phosphorylation and alternative splicing by modulating kinetic interactions of SRPK1 with molecular chaperones. Genes Dev 2009; 23:482-95; PMID:19240134; http://dx.doi.org/10.1101/gad.1752109.
33. Schwerk C, Prasad J, Degenhardt K, Erdjument- Bromage H, White E, Tempst P, et al. ASAP, a novel protein complex involved in RNA processing and apoptosis. Mol Cell Biol 2003; 23:2981- 90; PMID:12665594; http://dx.doi.org/10. 1128/MCB.23.8.2981-90.2003.
34. Joselin AP, Schulze-Osthoff K, Schwerk C. Loss of Acinus inhibits oligonucleosomal DNA fragmentation but not chromatin condensation during apoptosis. J Biol Chem 2006; 281:12475-84; PMID:16537548; http://dx.doi.org/10. 1074/jbc.M509859200.
35. Jiang ZH, Zhang WJ, Rao Y, Wu JY. Regulation of Ich-1 pre-mRNA alternative splicing and apoptosis by mammalian splicing factors. Proc Natl Acad Sci USA 1998; 95:9155-60; PMID:9689050; http://dx.doi.org/10.1073/pnas.95.16. 9155.
36. Fushimi K, Ray P, Kar A, Wang L, Sutherland LC, Wu JY. Upregulation of the proapoptotic caspase 2 splicing isoform by a candidate tumor suppressor, RBM5. Proc Natl Acad Sci USA 2008; 105:15708- 13; PMID:18840686; http://dx.doi.org/10.1073/pnas.0805569105.
37. Huang YP, Kim Y, Li Z, Fomenkov T, Fomenkov A, Ratovitski EA. AEC-associated p63 mutations lead to alternative splicing/protein stabilization of p63 and modulation of Notch signaling. Cell Cycle 2005; 4:1440-7; PMID:16177572; http://dx.doi.org/10.4161/cc.4.10.2086.
38. Chen Y, Zhang L, Jones KA. SKIP counteracts p53-mediated apoptosis via selective regulation of p21Cip1 mRNA splicing. Genes Dev 2011; 25:701- 16; PMID:21460037; http://dx.doi.org/10.1101/gad.2002611.
39. Edmond V, Brambilla C, Brambilla E, Gazzeri S, Eymin B. SRSF2 is required for sodium butyratemediated p21(WAF1) induction and premature senescence in human lung carcinoma cell lines. Cell Cycle 2011; 10:1968-77; PMID:21555914; http://dx.doi.org/10.4161/cc.10.12.15825.
40. Albers M, Kranz H, Kober I, Kaiser C, Klink M, Suckow J, et al. Automated yeast two-hybrid screening for nuclear receptor-interacting proteins. Mol Cell Proteomics 2005; 4:205-13; PMID:15604093; http:// dx.doi.org/10.1074/mcp. M400169-MCP200.
41. Gingras AC, Caballero M, Zarske M, Sanchez A, Hazbun TR, Fields S, et al. A novel, evolutionarily conserved protein phosphatase complex involved in cisplatin sensitivity. Mol Cell Proteomics 2005; 4:1725- 40; PMID:16085932; http://dx.doi.org/10.1074/mcp. M500231-MCP200.
42. Stewart JJ, White JT, Yan X, Collins S, Drescher CW, Urban ND, et al. Proteins associated with Cisplatin resistance in ovarian cancer cells identified by quantitative proteomic technology and integrated with mRNA expression levels. Mol Cell Proteomics 2006; 5:433- 43; PMID:16319398; http://dx.doi.org/ 10.1074/mcp.M500140-MCP200.
43. Tu LC, Yan X, Hood L, Lin B. Proteomics analysis of the interactome of N-myc downstream regulated gene 1 and its interactions with the androgen response program in prostate cancer cells. Mol Cell Proteomics 2007; 6:575-88; PMID:17220478; http://dx.doi.org/10.1074/mcp.M600249-MCP200.
44. Chavez JD, Hoopmann MR, Weisbrod CR, Takara K, Bruce JE. Quantitative proteomic and interaction network analysis of cisplatin resistance in HeLa cells. PLoS ONE 2011; 6:19892; PMID:21637840; http://dx.doi.org/10.1371/journal. pone.0019892.
45. Gatti L, Zunino F. Overview of tumor cell chemoresistance mechanisms. Methods Mol Med 2005; 111:127- 48; PMID:15911977.
46. Righetti PG, Castagna A, Antonioli P, Cecconi D, Campostrini N, Righetti SC. Proteomic approaches for studying chemoresistance in cancer. Expert Rev Proteomics 2005; 2:215-28; PMID:15892566; http:// dx.doi.org/10.1586/14789450.2. 2.215.
47. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene 2012; 31:1869-83; PMID:21892204; http://dx.doi.org/10.1038/onc.2011.384.
48. Sen T, Sen N, Brait M, Begum S, Chatterjee A, Hoque MO, et al. ΔNp63α confers tumor cell resistance to cisplatin treatment through the AKT transcriptional regulation. Cancer Res 2011; 71:1167-76; PMID:21266360; http://dx.doi.org/10.1158/0008-5472.CAN-10-1481.
49. Chandler DS, Singh RK, Caldwell LC, Bitler JL, Lozano G. Genotoxic stress induces coordinately regulated alternative splicing of the p53 modulators MDM2 and MDM4. Cancer Res 2006; 66:9502-8; PMID:17018606; http://dx.doi.org/10.1158/ 0008-5472.CAN-05-4271.
50. Hayes GM, Carrigan PE, Beck AM, Miller LJ. Targeting the RNA splicing machinery as a novel treatment strategy for pancreatic carcinoma. Cancer Res 2006; 66:3819-27; PMID:16585209; http://dx.doi.org/10.1158/0008-5472.CAN-05- 4065.
51. Ezponda T, Pajares MJ, Agorreta J, Echeveste JI, López-Picazo JM, Torre W, et al. The oncoprotein SF2/ASF promotes non-small cell lung cancer survival by enhancing survivin expression. Clin Cancer Res 2010; 16:4113-25; PMID:20682707; http://dx.doi.org/10.1158/1078-0432.CCR-10-0076.
52. Edmond V, Moysan E, Khochbin S, Matthias P, Brambilla C, Brambilla E, et al. Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin. EMBO J 2011; 30:510- 23; PMID:21157427; http://dx.doi.org/10.1038/ emboj.2010.333.
53. Shkreta L, Michelle L, Toutant J, Tremblay ML, Chabot B. The DNA damage response pathway regulates the alternative splicing of the apoptotic mediator Bcl-x. J Biol Chem 2011; 286:331-40; PMID:20980256; http://dx.doi.org/10.1074/ jbc.M110.162644.
54. Huang YP, Chuang A, Hao H, Talbot CC, Trink B, Sidransky D, et al. Phospho-ΔNp63α is a key regulator of cisplatin-induced microRNAome in head and neck squamous cell carcinoma cells. Cell Death Differ 2011; 18:1220-30; PMID:21274007; http://dx.doi.org/10.1038/cdd.2010.188.
55. Blaustein M, Pelisch F, Tanos T, Muñoz MJ, Wengier D, Quadrana L, et al. Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT. Nat Struct Mol Biol 2005; 12:1037-44; PMID:16299516;http://dx.doi.org/ 10.1038/nsmb1020.
56. Hu Y, Yao J, Liu Z, Liu X, Fu H, Ye K. Akt phosphorylates acinus and inhibits its proteolytic cleavage, preventing chromatin condensation. EMBO J 2005; 24:3543-54; PMID:16177823; http://dx.doi.org/10.1038/sj.emboj.7600823.
57. Singh KK, Erkelenz S, Rattay S, Dehof AK, Hildebrandt A, Schulze-Osthoff K, et al. Human SAP18 mediates assembly of a splicing regulatory multiprotein complex via its ubiquitin-like fold. RNA 2010; 16:2442-54; PMID:20966198; http://dx.doi.org/10.1261/rna.2304410.
58. Mazan-Mamczarz K, Galbán S, López de Silanes I, Martindale JL, Atasoy U, Keene JD, et al. RNA-binding protein HuR enhances p53 translation in response to ultraviolet light irradiation. Proc Natl Acad Sci USA 2003; 100:8354-9; PMID:12821781; http://dx.doi.org/10.1073/pnas.1432104100.
59. Shu L, Yan W, Chen X. RNPC1, an RNA-binding protein and a target of the p53 family, is required for maintaining the stability of the basal and stress-induced p21 transcript. Genes Dev 2006; 20:2961- 72; PMID:17050675; http://dx.doi.org/10.1101/gad.1463306.
60. Cho SJ, Zhang J, Chen X. RNPC1 modulates the RNA-binding activity of, and cooperates with, HuR to regulate p21 mRNA stability. Nucleic Acids Res 2010; 38:2256-67; PMID:20064878; http://dx.doi.org/10.1093/nar/gkp1229.
61. Zhang J, Jun Cho S, Chen X. RNPC1, an RNA-binding protein and a target of the p53 family, regulates p63 expression through mRNA stability. Proc Natl Acad Sci USA 2010; 107:9614-9; PMID:20457941; http://dx.doi.org/10.1073/pnas. 0912594107.
62. Kuzmichev A, Zhang Y, Erdjument-Bromage H, Tempst P, Reinberg D. Role of the Sin3-histone deacetylase complex in growth regulation by the candidate tumor suppressor p33(ING1). Mol Cell Biol 2002; 22:835-48; PMID:11784859; http://dx.doi.org/10.1128/MCB.22.3.835-48.2002.
63. Sykes SM, Mellert HS, Holbert MA, Li K, Marmorstein R, Lane WS, et al. Acetylation of the p53 DNA binding domain regulates apoptosis induction. Mol Cell 2006; 24:841-51; PMID:17189187; http://dx.doi.org/10.1016/j.molcel.2006.11. 026.
64. Tang Y, Luo J, Zhang W, Gu W. Tip60-dependent acetylation of p53 modulates the decision between cell cycle arrest and apoptosis. Mol Cell 2006; 24:827-39; PMID:17189186; http://dx.doi.org/10.1016/j.molcel.2006.11.021.
65. Miyamoto N, Izumi H, Noguchi T, Nakajima Y, Ohmiya Y, Shiota M, et al. Tip60 is regulated by circadian transcription factor clock and is involved in cisplatin resistance. J Biol Chem 2008; 283:18218- 26; PMID:18458078; http://dx.doi.org/10.1074/jbc.M802332200.
66. Maiuri MC, Galluzzi L, Morselli E, Kepp O, Malik SA, Kroemer G. Autophagy regulation by p53. Curr Opin Cell Biol 2010; 22:181-5; PMID:20044243; http://dx.doi.org/10.1016/j.ceb.2009.12.001.
67. Morselli E, Shen S, Ruckenstuhl C, Bauer MA, Mariño G, Galluzzi L, et al. p53 inhibits autophagy by interacting with the human ortholog of yeast Atg17, RB1CC1/FIP200. Cell Cycle 2011; 10:2763- 9; PMID:21775823; http://dx.doi.org/10.4161/cc.10.16.16868.
68. Sen T, Chang X, Sidransky D, Chatterjee A. Regulation of ΔNp63α by NFκB. Cell Cycle 2010; 9:4841- 7; PMID:21088498; http://dx.doi.org/10.4161/ cc.9.24.14093.
69. Bagnoli M, De Cecco L, Granata A, Nicoletti R, Marchesi E, Alberti P, et al. Identification of a chrXq27.3 microRNA cluster associated with early relapse in advanced stage ovarian cancer patients. Oncotarget 2011; 2:1265-78; PMID:22246208.
70. Neilsen PM, Noll JE, Suetani RJ, Schulz RB, Al-Ejeh F, Evdokiou A, et al. Mutant p53 uses p63 as a molecular chaperone to alter gene expression and induce a pro-invasive secretome. Oncotarget 2011; 2:1203-17;PMID:22203497.
71. Ory B, Ellisen LW. A microRNA-dependent circuit controlling p63/p73 homeostasis: p53 family crosstalk meets therapeutic opportunity. Oncotarget 2011; 2:259-64; PMID:21436470.
72. Nijwening JH, Kuiken HJ, Beijersbergen RL. Screening for modulators of cisplatin sensitivity: unbiased screens reveal common themes. Cell Cycle 2011; 10:380- 6; PMID:21239890; http://dx.doi.org/10.4161/cc.10.3.14642.
73. Jeong JS, Jiang L, Albino E, Marrero J, Rho HS, Hu J, et al. Rapid identification of monospecific monoclonal antibodies using a human proteome microarray. Mol Cell Proteomics 2012; In press; PMID:22307071; http://dx.doi.org/10.1074/mcp.O111.016253.